Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments' Substack by Kontra. In this article, we will summarize the bull's thesis on NVO. Novo Nordisk A/S's share was trading at $70.73 as of June 24th. NVO's trailing and forward P/E were 19.24 and 17.09, respectively, according to Yahoo Finance.
A picture of a pharma technician preparing an IV injection of a biopharmaceutical product.
Novo Nordisk continues to solidify its leadership in obesity treatment with groundbreaking clinical results and strategic clarity, reinforcing its position as a cornerstone healthcare investment. At the 2025 ADA Scientific Sessions, the company unveiled exceptional data from the REDEFINE 1 trial of its new combination therapy, CagriSema, which achieved a mean weight loss of 22.7% at 68 weeks.
Over 60% of patients lost more than 20% of their body weight, with 23% exceeding a 30% reduction—figures that set a new benchmark in obesity care. CagriSema's strong efficacy is coupled with a favorable safety profile, with only 6% of participants discontinuing treatment due to mostly mild gastrointestinal issues. Novo's innovation pipeline also features amycretin, a dual GLP-1 and amylin receptor agonist, showing promising early-stage data for sustained weight loss and further diversifying its leadership in metabolic health.
Financially, Novo Nordisk remains highly attractive, with revenues expected to grow from DKK 330 billion in 2025 to DKK 520 billion by 2029, alongside EBIT margins projected around 50%. Valuation metrics support the bullish case: its forward P/E is forecast to decline from 17x in 2025 to under 10x by 2029, and EV/EBITDA from 12.6x to 6.6x. Dividend yields are set to increase steadily, and free cash flow is projected to reach DKK 174 billion by 2029.
Novo Nordisk's disciplined capital allocation, strong innovation, and regulatory integrity highlight its potential for long-term outperformance. The company remains a premier name in global healthcare, offering both resilience and upside for investors seeking quality growth.
Previously, we covered a on Novo Nordisk A/S by Kontra Investments in May 2025, which highlighted its GLP-1 market dominance, strong Q1 results, and resilience against U.S. headwinds. The company's stock price has appreciated by approximately 4.4% since our coverage. The thesis still stands as Novo's pipeline and financial strength continue to support long-term growth. Kontra shares an identical view but emphasizes CagriSema's clinical data.
Novo Nordisk A/S is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 60 hedge fund portfolios held NVO at the end of the first quarter, which was 64 in the previous quarter. While we acknowledge the risk and potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
44 minutes ago
- CBS News
Timberwolves select center Joan Beringer with 17th pick of NBA draft
The Timberwolves on Wednesday night picked their first player under the leadership of new owners Marc Lore and Alex Rodriguez. With the No. 17 pick in the NBA draft, the Wolves selected Joan Beringer. The 6-foot-11, 230-pound center, originally from France, is only 18 and will work with another tall Frenchman, Rudy Gobert. According to the NBA, Beringer grew up playing soccer and claims he never touched a basketball until the summer of 2021. He says he tried out for basketball after being pressured by his friends, later joining the U17 team for Strasbourg Saint-Joseph Basket. Joan Beringer R of Cedevita Olimpija Ljubljana goes for a layup during the eighthfinals of the BKT Euro Cup 2024/25 between Cedevita Olimpija Ljubljana and Besiktas Fibabanka Istanbul in Ljubljana, Slovenia, March 5, 2025. Zeljko Stevanic/Xinhua via Getty Images Beringer joined Cedevita Olimpija last summer and averaged 5.1 points, 4.7 rebounds, and 1.4 blocks in 18.2 minutes across 54 appearances, helping the team win the 2024-25 Slovenian Basketball Cup. The pick comes just days after longtime Timberwolves owners Glen Taylor and his wife Becky said goodbye to the team after purchasing it for $88 million more than 30 years ago. On Tuesday, the NBA approved the $1.5 billion sale of the Wolves to an investment group led by Lore and Rodriguez.
Medscape
an hour ago
- Medscape
US Neonatal Mortality Rate: Unveiling the Perinatal Causes
TOPLINE: The neonatal mortality rate in the US decreased from 1999 to 2022, with deaths from interstitial emphysema and related conditions showing the steepest decline, yet mortality from slow fetal growth and malnutrition rose by nearly 2% annually. METHODOLOGY: A retrospective study was conducted to examine neonatal mortality rates from 1999 to 2022 using data sourced from CDC Wide-Ranging Online Data for Epidemiologic Research, with diagnostic codes used to identify the cause of death related to perinatal complications. The top 10 causes of neonatal death were identified based on cumulative frequency over the study period. Mortality rates were stratified by sex, delivery method, birthplace, and age at death. TAKEAWAY: From 1999 to 2022, 283,696 neonatal deaths were reported owing to perinatal complications, with male neonates accounting for 56.2% of deaths. The top 10 causes accounted for 79.8% of the deaths. Disorders related to short gestation and low birth weight were the leading cause of neonatal deaths, with a crude rate of 102.10 per 100,000 live births. They were followed by deaths in newborns due to maternal complications of pregnancy and issues related to the placenta, cord, and membranes. Mortality from interstitial emphysema and related conditions showed a steep decline, followed by respiratory distress from the perinatal period, with annual average percent changes of -5.40% (95% CI, -6.20% to -4.64%) and -3.63% (95% CI, -4.45 to -3.00), respectively. Mortality from slow fetal growth and fetal malnutrition increased by 1.91% annually (95% CI, 0.46%-3.82%), whereas mortality due to maternal complications and bacterial sepsis in newborns remained stable. IN PRACTICE: 'US neonatal mortality has generally decreased, likely due to medical advancements, improved prenatal care, and neonatal intensive care interventions.' the authors wrote. 'Vaginal deliveries were associated with nearly three times the neonatal mortality rate of cesarean deliveries, potentially due to complications, such as birth trauma and prolonged labor.' SOURCE: This study was led by Muzamil Khan, MD, of the George Washington University School of Medicine and Health Sciences in Washington, DC. It was published online on June 23, 2025, in JAMA Pediatrics. LIMITATIONS: This study could not assess important nutritional factors, such as exclusive breastfeeding rates, which may influence malnutrition outcomes. It focused only on perinatal causes influenced by healthcare and excluded congenital malformations. Each death was assigned a single diagnostic code, limiting the capture of coexisting conditions. DISCLOSURES: No funding source or conflicts of interest were disclosed by the authors. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Meta hires three OpenAI researchers, WSJ reports
(Reuters) -Meta Chief Executive Mark Zuckerberg has hired three OpenAI researchers to join his superintelligence efforts, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. The company hired Lucas Beyer, Alexander Kolesnikov and Xiaohua Zhai, who were all working in OpenAI's Zurich office, the report said. Reuters could not immediately verify the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
